Pharma & Biotech Global Week in Review 7 Sept 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas)

US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

10 considerations in a life sciences license (Richard C. Hsu)

US wary of WIPO initiative to host meeting on avian influenza and intellectual property rights (2005) (KEI)

Surprisingly excellent analysis of PhRMA’s 2009 Special 301 filing on Poland by US Embassy in Warsaw (KEI)

Cable: US Government collaboration with drug companies to lobby the Finnish Parliament on drug pricing legislation (KEI)

Wikileaks cables on the US opposition to Philippines legislation on affordable medicines (KEI)

Implementing the Jordan FTA rules on exclusive rights in regulatory test data (KEI)

Data protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2) (BIOtechNOW)

EU: Merck v Deutsches Patent Case C-125/10 – a case note (The SPC Blog)

New Zealand measures to prevent parallel trade in medicine from NZ to US (KEI)

US: FDA issues report to Congress on findings and recommendations of rare and neglected tropical disease groups; groups report strengths and opportunities to improve regulatory paradigms and science (FDA Law Blog)

US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book Blog)

US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas)

US: The CoreValve compulsory license on patent to treat aortic stenosis: District Court Delaware judgment in Edwards Lifesciences v CoreValve (KEI)

 

Products

AndroGel (Testosterone) – US: Citizen petition requests rulemaking process for 505(b)(2) NDA therapeutic equivalence rating decisions (FDA Law Blog)

Atorvastatin – EU: T 777/08: When is a polymorph inventive? (Kluwer Patent Blog)

Donepezil – Spain: How useful are undertakings not to launch? (Kluwer Patent Blog)

Fortical (Calcitonin-salmon) – US: Obviousness in chemical formulations: (unclaimed) purpose of limitation leads to nonobviousness holding: Unigene Labs. and Upsher-Smith Labs v. Apotex (Patently-O)

Glivec (Imatinib mesylate) – India: The Glivec patent saga – its raining recusals (Spicy IP)

Glivec (Imatinib mesylate) – India: Supreme Court to hear Novartis challenge to India’s patent law (IP Watch)

Lo Loestrin Fe (Norethindrone acetate / Ethinyl estradiol / Ferrous fumarate) – US: Warner Chilcott files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs)

Lumigan (Bimatoprost) – US: Allergan files patent infringement suit against Sandoz following Para IV certification filing (Patent Docs)

Megace ES (Megestrol acetate) – US: Par Pharmaceuticals files patent infringement suits against TWI Pharmaceuticals in ND Illinois and Maryland in response to Para IV certification (Patent Docs)

Memantine – EU: Synthon ruling “raises inevitable concerns” (The SPC Blog)

Nexavar (Sorafenib) – India: NATCO files compulsory license against Bayer’s Nexavar (Spicy IP)

Nuedexta (Dextromethorphan hydrobromide / Quinidine sulphate) – US: Avanir files patent infringement complaints against Impax and Wockhardt in response to Para IV certification filing (Patent Docs)

Tamiflu (Oseltamivir phosphate) – US: Gilead files patent infringement complaint against Natco in response to Para IV certification filing (Patent Docs)

Tricor (Fenofibrate) – US: Abbott and EDT Pharma file separate patent infringement complaints in New Jersey against Mylan following Para IV certification (Patent Docs)

Viagra (Sildenafil) – US: District Court E D Virginia: Does a “beneficial” patent owner have standing?: Pfizer v Teva (Property, intangible)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: